Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with Non-Valvular Paroxysmal Atrial Fibrillation not receiving anticoagulant therapy

International Heart Journal

Volumn 55, Issue 2, 2014, Pages 119-125

  Komatsu, Takashi ^a   Sato, Yoshihiro ^a   Ozawa, Mahito ^a   Kunugita, Fusanori ^a   Yoshizawa, Reisuke ^a   Morino, Yoshihiro ^a   Nakamura, Motoyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Prognosis; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; APRINDINE; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CIBENZOLINE; DIGITALIS; DISOPYRAMIDE; FLECAINIDE; GLUCOSE; HEMOGLOBIN A1C; PILSICAINIDE; PIRMENOL; PROPAFENONE; VERAPAMIL;

AGED; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BRAIN ISCHEMIA; CHA2DS2 VASC SCORE; CHADS2 SCORE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STRATIFICATION; SURVIVAL RATE; THORAX RADIOGRAPHY; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; JAPAN; METHODOLOGY; PAROXYSMAL TACHYCARDIA; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CARDIAC CATHETERIZATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TACHYCARDIA, PAROXYSMAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897080036     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-242     Document Type: Article

References (34)

1. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37: 371-8. (Review)
2. Ohsawa M, Okayama A, Sakata K, et al. Rapid increase in estimated number of persons with atrial fibrillation in Japan: an analysis from national surveys on cardiovascular disease in 1980, 1990 and 2000. J Epidemiol 2005; 15: 194-6.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987; 147: 1561-4.
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32: 695-703.
5. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-354.
6. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
7. Sopher SM, Camm AJ. Atrial fibrillation: maintenance of sinus rhythm versus rate control. Am J Cardiol 1996; 77: 24A-37A. (Review)
8. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009). Hypertens Res 2009; 32: 3-107.
9. Investigating Committee of Guideline for Diagnosis and Treatment of Hyperlipidemias, Japan Atherasclerosis Society. J Jpn Atheroscler Soc 1997; 25: 1-34.
10. Komatsu T, Tachibana H, Sato Y, Ozawa M, Nakamura M, Okumura K. Effi cacy of amiodarone for preventing the recurrence of symptomatic paroxysmal and persistent atrial fibrillation after cardioversion. Circ J 2007; 71: 46-51.
11. Kodama H, Aisawa Y, Inoue H, et al. Guideline for Drug Treatment of Arrhythmias (JCS 2004). Circ J 2004; 68: 981-1053.
12. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-91.
13. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55.
14. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
15. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84: 527-39.
16. Tomita F, Kohya T, Sakurai M, et al. Prevalence and clinical characteristics of patients with atrial fibrillation: analysis of 20,000 cases in Japan. Jpn Circ J 2000; 64: 653-8.
17. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Trial. Stroke 2006; 37: 447-51.
18. Komatsu T, Sato Y, Tachibana H, Ozawa M, et al. Relationship between CHADS2 score and effi cacy of antiarrhythmic drug therapy in patients with paroxysmal atrial fibrillation. Circ J 2013; 77: 639-45.
19. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugita F, Nakamura M. Effi cacy of antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term cardiovascular prognosis in patients with asymptomatic paroxysmal atrial fibrillation. Int Heart J 2010; 51: 98-104.
20. Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 2012; 172: 997-1004.
21. Ogawa S, Aisawa Y, Atarashi H, et al. Guidelines for Pharmacotherapy of Atrial Fibrillation (JCS 2008). Circ J 2008; 72: 1581-638.
22. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006; 367: 1903-12.
23. Atrial Fibrillation Investigators. Risk factors for stroke and effi cacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
24. Komatsu T, Tachibana H, Satoh Y, Ozawa M, Kunugita F, Nakamura M. Clinical profi les, effi cacy of antiarrhythmic drug therapy and cardiovascular prognosis in patients with fi rst detected paroxysmal atrial fibrillation. Int Heart J 2011; 52: 32-8.
25. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-45.
26. Connolly SJ, Pogue J, Eikelboom J, et al; ACTIVE W Investigators. Benefi t of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-37.
27. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Registry. Circ J 2011; 75: 1328-33.
28. Komatsu T, Tachibana H, Sato Y, et al. Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. Int Heart J 2010; 51: 24-9.
29. Komatsu T, Tachibana H, Sato Y, et al. Relationship between CHA2DS2-VASc scores and ischemic stroke/cardiovascular events in Japanese patients with paroxysmal atrial fibrillation not receiving anticoagulant therapy. J Cardiol 2012; 59: 321-8.
30. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99: 295-304. (Review)
31. Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038-45. (Review)
32. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30: 1223-9.
33. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.
34. Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124.